Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-115 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| PRX-115 | BIOLOGICAL | intravenous (IV) infusion |
| Methotrexate (MTX) | DRUG | Oral MTX 15 mg weekly |
| PRX-115 placebo | OTHER | intravenous (IV) infusion |
| Placebo-Methotrexate | OTHER | Oral Placebo-MTX weekly |
| Placebo | DRUG | Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8 |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Protalix BioTherapeutics, Inc. (DE) | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | Pegylated Recombinant Candida Utilis Uricase |
PRX-115 is an investigational small molecule being developed for the treatment of gout. It is designed to target urate, the underlying cause of the condition. The drug is currently in Phase 2 clinical development and has not yet been approved by regulatory authorities.
PRX-115 targets urate, which is the molecular target relevant to gout. By acting on urate, the drug aims to address elevated uric acid levels associated with the condition. This mechanism is central to its potential therapeutic effect in gout patients.
PRX-115 is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for gout.
PRX-115 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The drug is being studied in clinical trials to assess its safety and effectiveness in patients with gout.
PRX-115 is being evaluated in two clinical trials. The Phase 2 trial, NCT07280156, is recruiting 150 adults with gout and is studying different dosing regimens with and without methotrexate versus placebo. A Phase 1 trial, NCT05745727, has been completed and enrolled 64 volunteers with elevated uric acid levels.